keyword
MENU ▼
Read by QxMD icon Read
search

Alopecia totalis

keyword
https://www.readbyqxmd.com/read/28704810/long-term-prognosis-of-alopecia-totalis-and-alopecia-universalis-a-longitudinal-study-with-more-than-10-years-of-follow-up-better-than-reported
#1
Yong Hyun Jang, Nam-Soo Hong, Sun Young Moon, Dong Hyuk Eun, Won Kee Lee, Seong Geun Chi, Jun Young Kim, Weon Ju Lee, Seok-Jong Lee, Do Won Kim
BACKGROUND: In alopecia totalis (AT) and alopecia universalis (AU), the chance of full hair regrowth is known to be less than 10%. However, this information is based on a few older studies conducted in the 1950s and 1960s. OBJECTIVE: We investigated the current long-term prognosis of individuals with AT/AU. METHODS: A retrospective chart review was performed in patients with AT/AU between 1994 and 2005. Outcome data were collected by reviewing outpatient clinical files or by phone interviews...
July 14, 2017: Dermatology: International Journal for Clinical and Investigative Dermatology
https://www.readbyqxmd.com/read/28636882/foxn1-italian-founder-mutation-in-indian-family-implications-in-prenatal-diagnosis
#2
Akella Radha Rama Devi, Nagesh Narayan Panday, Shaik Mohammad Naushad
The Forkhead box N1 (FOXN1) is a transcriptional factor regulating the development, differentiation and function of thymic epithelial cells; maintaining T-lineage progenitors in bone marrow; promoting terminal differentiation of epithelial cells of hair follicles. Mutation in FOXN1 was reported to cause a rare disorder characterized by rudimentary thymus gland, T-cell immunodeficiency, congenital alopecia and nail dystrophy within an Italian community. This is the first report of FOXN1 p.R255X mutation from India, outside this endogamous Italian community...
June 18, 2017: Gene
https://www.readbyqxmd.com/read/28635319/a-case-of-topical-ruxolitinib-treatment-failure-in-alopecia-areata
#3
Maya Deeb, Renée A Beach
Alopecia areata (AA) is an autoimmune-mediated, nonscarring form of hair loss. Despite its prevalence, current management options are limited, especially when the disease has progressed to alopecia totalis (AT) or alopecia universalis (AU). Recent evidence that janus kinase (JAK) signaling contributes to AA pathogenesis prompted the investigation of JAK inhibitors such as tofacitinib and ruxolitinib as possible oral treatments. However, the potential for significant adverse effects with systemic JAK inhibition makes local administration a more attractive option...
June 1, 2017: Journal of Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/28627278/methotrexate-for-the-treatment-of-pediatric-alopecia-areata
#4
Erin T Landis, Rita O Pichardo-Geisinger
PURPOSE: Alopecia areata is a form of nonscarring hair loss that occurs in pediatric and adult patients, with presentation varying from round or ovoid patches of alopecia to alopecia totalis or universalis. While frustrating for patients, it can also be frustrating for clinicians to treat, as there is no definitive treatment. Dermatologists are very familiar with the use of methotrexate for psoriasis and other inflammatory skin diseases, and this medication is generally well tolerated in children...
June 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28378336/review-of-treatment-for-alopecia-totalis-and-alopecia-universalis
#5
REVIEW
Sama Kassira, Dorota Z Korta, Lance W Chapman, Francis Dann
Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. This review focuses on the evidence for current treatment options for AT and AU. The PubMed database was searched from January 1, 2000, to September 1, 2016, for clinical trials, retrospective studies, and case reports of treatments for AT and AU...
August 2017: International Journal of Dermatology
https://www.readbyqxmd.com/read/28319079/permanent-diffuse-alopecia-after-haematopoietic-stem-cell-transplantation-in-childhood
#6
D Bresters, D C M Wanders, M Louwerens, L M Ball, M Fiocco, R van Doorn
Permanent alopecia after haematopoietic stem cell transplantation (HSCT) is distressing and few studies have investigated this late effect. The aim of the study was to assess the percentage of patients with alopecia and investigate risk factors for alopecia. Patients who underwent allogeneic HSCT before age 19 years, from January 1990 to January 2013, who were at least 2 years after transplant and in follow-up in our clinic were included. Alopecia was defined as clinically apparent decreased hair density. Possible risk factors considered for alopecia after HSCT included: gender, age, diagnosis, donor type, conditioning regimen: cranial irradiation (TBI/cranial radiotherapy) and/or chemotherapy, which chemotherapeutic agents were used and acute/chronic GvHD...
March 20, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28140540/sequential-high-and-low-dose-systemic-corticosteroid-therapy-for-severe-childhood-alopecia-areata
#7
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
BACKGROUND: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Following initial pulse therapy, continuation of corticosteroid therapy at a dose below the Cushing threshold might be able to suppress disease activity without causing severe side effects...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28140533/kombinierte-hoch-niedrig-dosis-therapie-mit-systemischen-glukokor-tikoiden-bei-schweren-verlaufsformen-der-alopecia-areata-im-kindesalter
#8
Karin Jahn-Bassler, Wolfgang Michael Bauer, Franz Karlhofer, Matthias G Vossen, Georg Stingl
HINTERGRUND: Schwere Verlaufsformen der Alopecia areata (AA) im Kindesalter sind aufgrund limitierter Optionen therapeutisch herausfordernd. Systemische, hochdosierte Glukokortikoide weisen die schnellste Ansprechrate auf, nach dem Absetzen kommt es allerdings zu Rezidiven. Eine längerfristige Hochdosis-Anwendung ist aufgrund der zu erwartenden Nebenwirkungen nicht empfehlenswert. Eine dauerhafte Steroiderhaltungstherapie unterhalb der Cushing-Schwellen-Dosis nach Bolustherapie könnte die Krankheitsaktivität ohne Nebenwirkungen längerfristig unterdrücken...
January 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27826988/treatment-of-corticosteroid-refractory-alopecia-totalis-with-oral-tacrolimus
#9
E Verga, C Hayes, A Liakopoulou, R Verdolini
No abstract text is available yet for this article.
November 9, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/27816293/tofacitinib-for-the-treatment-of-severe-alopecia-areata-and-variants-a-study-of-90-patients
#10
Lucy Y Liu, Brittany G Craiglow, Feng Dai, Brett A King
BACKGROUND: Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. OBJECTIVE: We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time. METHODS: This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment...
January 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27730032/serum-vitamin-d-in-patients-with-alopecia-areata
#11
Ola Ahmed Bakry, Shawky M El Farargy, Maathir K El Shafiee, Amira Soliman
BACKGROUND: Alopecia areata (AA) is a common, recurrent, autoimmune hair disorder. It has been found that vitamin D deficiency is associated with many autoimmune diseases. AIMS: The current study aimed to estimate serum levels of 25-hydroxy vitamin D in patients with AA. MATERIALS AND METHODS: This case-control study included 60 patients with AA and 60 age, gender, skin phototype, and body mass index-matched healthy subjects as a control group...
September 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27699252/safety-and-efficacy-of-the-jak-inhibitor-tofacitinib-citrate-in-patients-with-alopecia-areata
#12
Milène Kennedy Crispin, Justin M Ko, Brittany G Craiglow, Shufeng Li, Gautam Shankar, Jennifer R Urban, James C Chen, Jane E Cerise, Ali Jabbari, Mårten C G Winge, M Peter Marinkovich, Angela M Christiano, Anthony E Oro, Brett A King
BACKGROUND: Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8(+) T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined. METHODS: This was a 2-center, open-label, single-arm trial using the pan-JAK inhibitor, tofacitinib citrate, for AA with >50% scalp hair loss, alopecia totalis (AT), and alopecia universalis (AU)...
September 22, 2016: JCI Insight
https://www.readbyqxmd.com/read/27608049/alopecia-areata-totalis-and-universalis-a-multicenter-review-of-132-patients-in-spain
#13
S Vañó-Galván, P Fernández-Crehuet, R Grimalt, M J Garcia-Hernandez, R Rodrigues-Barata, S Arias-Santiago, A Molina-Ruiz, E Garcia-Lora, J Dominguez-Cruz, A Brugues, J Ferrando, C Serrano-Falcón, S Serrano, J Paoli, F Camacho
BACKGROUND: Alopecia areata totalis (AAT) and universalis (AAU) pose a therapeutic challenge. OBJECTIVE: To describe the clinical and epidemiological features, therapeutic response and prognostic factors in a large series of patients diagnosed with AAT and AAU. METHODS: This retrospective multicenter study included patients diagnosed with AAT/AAU with a minimum follow-up of 12 months. Response was assessed based on the regrowth of scalp hair...
March 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27503140/beard-alopecia-areata-a-multicentre-review-of-55-patients
#14
REVIEW
D Saceda-Corralo, R Grimalt, P Fernández-Crehuet, A Clemente, C Bernárdez, M J García-Hernandez, S Arias-Santiago, A R Rodrigues-Barata, A Rodríguez-Pichardo, E García-Lora, P Jaén, F M Camacho, S Vañó-Galván
BACKGROUND: Alopecia areata on the beard area (BAA) is a common clinical manifestation, but there are no studies about its characteristics. OBJECTIVE: To describe the epidemiology, comorbidities, clinical presentation, evolution, diagnostic findings and therapeutic choices in a series of patients with BAA. METHODS: This retrospective multicentre review included patients diagnosed with BAA as the first and unique clinical manifestation with at least 12 months of follow-up...
January 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27322477/molecular-signatures-define-alopecia-areata-subtypes-and-transcriptional-biomarkers
#15
Ali Jabbari, Jane E Cerise, James C Chen, Julian Mackay-Wiggan, Madeleine Duvic, Vera Price, Maria Hordinsky, David Norris, Raphael Clynes, Angela M Christiano
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human scalp skin biopsy specimens from AA or normal control subjects. Based on gene expression profiling, samples formed distinct clusters based on the presence or absence of disease as well as disease phenotype (patchy disease compared with alopecia totalis or universalis). Differential gene expression analysis allowed us to robustly demonstrate graded immune activity in samples of increasing phenotypic severity and generate a quantitative gene expression scoring system that classified samples based on interferon and cytotoxic T lymphocyte immune signatures critical for disease pathogenesis...
May 2016: EBioMedicine
https://www.readbyqxmd.com/read/27306107/efficacy-of-tofacitinib-in-treatment-of-alopecia-universalis-in-two-patients
#16
A K Gupta, J L Carviel, W Abramovits
BACKGROUND: Autoimmune-triggered non-scarring hair loss is a feature of alopecia areata (AA). Initially patchy and often self-limited, severe hair loss forms include the complete loss of scalp hair or alopecia totalis (AT) and complete loss of all hair or alopecia universalis (AU). For AT and AU a reliable treatment has remained elusive. The targeted kinase inhibitor tofacitinib, in current use for treatment of other immune diseases, has been hypothesized as a viable option for AA, AT and AU therapy and a few case reports support this...
August 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27279512/severe-subtype-of-alopecia-areata-is-highly-associated-with-thyroid-autoimmunity
#17
Ghada A Bin Saif
OBJECTIVES: To assess the significance of thyroid autoimmune screening in alopecia areata (AA) patients in Saudi population, and to determine whether there is a difference in thyroid autoimmune susceptibility between mild and severe AA. METHODS: In a prospective case-control study, we included 50 alopecia totalis (AT) and alopecia universalis (AU) patients, 50 age- and gender-matched patients with localized AA, and 50 age- and gender- matched healthy subjects between March 2015 and August 2015...
June 2016: Saudi Medical Journal
https://www.readbyqxmd.com/read/27085229/pulse-corticosteroid-therapy-with-oral-dexamethasone-for-the-treatment-of-adult-alopecia-totalis-and-universalis
#18
LETTER
Sergio Vañó-Galván, Ángela Hermosa-Gelbard, Natalia Sánchez-Neila, Laura Miguel-Gómez, David Saceda-Corralo, Rita Rodrigues-Barata, Dong-Lai Ma, Pedro Jaén
No abstract text is available yet for this article.
May 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27051848/hydroxychloroquine-is-ineffective-in-treatment-of-alopecia-totalis-and-extensive-alopecia-areata-a-case-series-of-8-patients
#19
Christoffer V Nissen, Hans Christian Wulf
No abstract text is available yet for this article.
March 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/26994969/the-transient-role-for-calcium-and-vitamin%C3%A2-d-during-the-developmental-hair%C3%A2-follicle-cycle
#20
Leila J Mady, Dare V Ajibade, Connie Hsaio, Arnaud Teichert, Chak Fong, Yongmei Wang, Sylvia Christakos, Daniel D Bikle
The role for 1,25-dihydroxyvitamin D3 and/or calcium in hair follicle cycling is not clear despite their impact on keratinocyte differentiation. We found that calbindin-D9k null (knockout) pups generated from calbindin-D9k knockout females fed a vitamin D-deficient, low-calcium (0.47%) diet develop transient alopecia. The pups appear phenotypically normal until 13 days of age, after which the hair progressively sheds in a caudocephalic direction, resulting in truncal alopecia totalis by 20-23 days, with spontaneous recovery by 28 days...
July 2016: Journal of Investigative Dermatology
keyword
keyword
78622
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"